spark therapeutics leadership

Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline Joseph La Barge and Carol Greve-Philips expand business operations PHILADELPHIA, November 16, 2020 (GLOBE NEWSWIRE) — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer.His visionary leadership and more than 25 … BOARD MEMBERS. President and Head of R&D, Spark Therapeutics. This website uses cookies and similar technologies to optimize and improve the experience on our site (. The candidate will be responsible for leading, directing, and managing all upstream process development needs of Spark Therapeutics. Michael focused on corporate and business unit strategies, organizational transformations, product launches, growth strategies and new market entries. “I look forward to working with Spark and Roche leadership to navigate and accelerate the advancement of our science with a sustainable impact for patients, the healthcare system and society.”. But opting out of some of these cookies may have an effect on your browsing experience. PHILADELPHIA, November 16, 2020  (GLOBE NEWSWIRE) — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer. Jeff Marrazzo admitted to mixed emotions Tuesday as Roche closed its $4.3 billion acquisition of Spark Therapeutics, the gene therapy company he … ET Spark Therapeutics is an equal opportunity employer. Before that, Michael was senior vice president at Sanofi Diagnostics Pasteur in Paris and a senior director at Boehringer Mannheim (now Roche) in Mannheim, Germany. Reape is one of the senior Spark staffers hitting the exit in the aftermath of Roche’s $4.3 billion takeover. You also have the option to opt-out of these cookies. He was formerly the Chief Business Officer at Spark Therapeutics, Inc., a broad operating position he held since 2016. Media Contact: Co-Founder and CEO Spark Therapeutics. Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company leadership will present Phone: 1-855-SPARKTX / +1 215-220-9300. Spark Therapeutics, a late-stage, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today that it has expanded its leadership Steven Altschuler brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. Commercial gene therapy company Spark Therapeutics recently announced the appointments of two new leadership team members, a new chief medical officer and head of business development. Philadelphia, PA 19104 Prior to joining Bain in 2010, Michael was a partner at Monitor Group and head of the New York office, where he supported multiple pharmaceutical product launches and growth strategies for 10 years. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. Vin Milano. To lead in certain aspects of strategic planning, as designed by the ophthalmology leader. in molecular biology and a B.Sc. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer. kevin.giordano@sparktx.com About Spark Therapeutics At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. “After another year of incredible growth in our hometown of Philadelphia, we are poised to scale and accelerate our gene therapy research like never before as we create the path to the next generation of gene therapies,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “I admire the Spark team’s passion for the important role they play in delivering innovative gene therapies to patients, and I look forward to joining the company and making an impact on those patients’ lives,” Pussinen said in a statement. Greater Philadelphia. – Associate Editor, … Ali has 4 jobs listed on their profile. Responsibilities: 80 %. Life Science Cares’ solution is to leverage the extraordinary talent and passion of our industry to affect change. His visionary leadership and more than 25 years of experience, combined with Spark’s rich gene therapy expertise, further positions the company to reach broader patient populations affected by genetic disease. Ultimately to further Spark's commitment and dedication to being a leader in ocular gene therapy and to maintain Spark's leadership role in the US. Program Management Lead R & D ★ Relationship Building ★ Leadership at Spark Therapeutics, Inc. This role is a critical member of the Technology Leadership Team. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Dr. High was a co-founder of Spark Therapeutics, Inc. and served as its President and a member of its board of directors from September 2014 to December 2019 and served as its Head of Research & Development from September 2017 to February 2020. © 2021 GlobeNewswire, Inc. All Rights Reserved. Press Release Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer Published: Nov. 16, 2020 at 7:30 a.m. Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer Email Print Friendly Share November 16, 2020 07:30 ET | Source: Spark Therapeutics, Inc. Spark Therapeutics is seeking a highly talented individual to lead its Discovery platform and act as the driver of the innovation engine within Research. See if you qualify! He obtained a Bachelor of Commerce and Administration from Victoria University of Wellington. Easy 1-Click Apply (SPARK THERAPEUTICS) Technical Strategy & Operations Lead job in Philadelphia, PA. View job description, responsibilities and qualifications. The Global Medical Affairs Therapeutics Area Leader, Hematology is a critical member of the Medical Affairs leadership team and is responsible for defining the global Medical Affairs vision, strategies & tactics that support Spark's late stage hematology product development and … See if you qualify! Necessary cookies are absolutely essential for the website to function properly. in biochemistry from the University of Waterloo in Canada. Spark Therapeutics fact sheet. These cookies do not store any personal information. SPARK THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Coordinate facilitate connectivity, enable … Provide strategic and direct leadership to US, EU, and Rest-of-World (Novartis) Ophthalmology medical team members. Position is responsible for validation compliance leadership at the Branchburg, ... Lead for multiple technical operations functional areas at Spark Therapeutics, Inc. Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer Email Print Friendly Share November 16, 2020 07:30 ET | Source: Spark Therapeutics, Inc. The Global Medical Affairs Therapeutics Area Leader, Ophthalmology is a critical member of the Medical Affairs leadership team and is responsible for defining the global Medical Affairs vision, strategies & tactics that support the safe and appropriate use of LUXTURNA as well as Spark’s late stage Ophthalmology asset development. At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of … Spark Therapeutics Announces First Participant Dosed in Phase 1/2 trial of SPK-3006 First participant dosed in the RESOLUTE SM trial, a Phase 1/2 dose-escalation study of investigational SPK-3006 for late-onset Pompe disease . PHILADELPHIA, Dec. 05, 2016 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of John Furey to the newly created position of chief operating officer. Dr. High has served on our Board of Directors since June 2019. Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Spark Therapeutics is an equal opportunity employer. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (now part of Roche) for six … PHILADELPHIA, November 16, 2020 (GLOBE NEWSWIRE) — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic … Michael joins Spark Therapeutics from Bain & Company, where he served as a partner in the healthcare practice for a decade. Michael focused on corporate and business unit strategies, organizational transformations, product launches, growth strategies and new market entries. Prior to joining Bain in 2010, Michael was a partner at Monitor Group and head of the New York office, where he supported multiple pharmaceutical product launches and growth strategies for 10 years. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law. Chairman Life Science Cares Philadelphia CEO Idera Pharmaceuticals. Before that, Michael was senior vice president at Sanofi Diagnostics Pasteur in Paris and a senior director at Boehringer Mannheim (now Roche) in Mannheim, Germany. Biopharmaceutical executive and board member. The Higgins Group. Ultimately to further Spark's commitment and dedication to being a leader in ocular gene therapy and to maintain Spark's leadership role in the US. Michael Dougherty. in biochemistry from the University of Waterloo in Canada. Spark’s $4.8 billion acquisition deal with Roche in 2019 ended up being the city’s largest-ever exit for a venture-backed company. Attend pertinent medical/scientific conference and engage scientific/ medical KOLs on specific needs of ophthalmic strategy and Spark. “This is a pivotal time to spark unprecedented progress in the field of genetic medicine, anchored by strong collaboration and future planning,” said Retterath. Jeff Marrazzo. Dr. High was a co-founder of Spark Therapeutics, Inc. and served as its President and a member of its board of directors from September 2014 to December 2019 and served as its Head of Research & Development from September 2017 to February 2020. Jeff Marrazzo admitted to mixed emotions Tuesday as Roche closed its $4.3 billion acquisition of Spark Therapeutics, the gene therapy company … Spark Therapeutics, Inc. Apr 2020 - Present 11 months Associate Director Commercial ★ R & D ★ Relationship Building ★ CMC ★ Leadership PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SPARK THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. Spark Therapeutics co-founder Dr. Katherine High takes C-suite role at North Carolina gene therapy company. Read More His visionary leadership and more than 25 years of experience, combined with Spark’s rich gene therapy expertise, further positions the company to reach broader patient populations affected by genetic disease. ET “We are thrilled to have Michael at the helm of our long-term strategy as we approach nearly one year since close of the merger with Roche and aim to further leverage the global resources of Roche to accelerate our vision of a world where no life is limited by genetic disease.”Michael joins Spark Therapeutics from Bain & Company, where he served as a partner in the healthcare practice for a decade. We currently have four programs in clinical trials. PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer.His visionary leadership and more than 25 years of … These cookies will be stored in your browser only with your consent. Michael earned an MBA from the Institut Européen d’Administration des Affaires (INSEAD) and holds a M.Sc. Oversee meeting preparation and planning for internal and external committees, leadership and Corporate Management meetings. About Spark Therapeutics We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law. High. “We are thrilled to have Michael at the helm of our long-term strategy as we approach nearly one year since close of the merger with Roche and aim to further leverage the global resources of Roche to accelerate our vision of a world where no life is limited by genetic disease.”. Dr. Katherine A. Sir Brian Joseph Roche KNZM is a New Zealand business executive.. Roche was born in the Hawke's Bay.He attended St John's College in Hastings. Spark Therapeutics’ chief medical officer Kathy Reape is set to leave the biotech. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. May represent Spark and manage aspects of collaborations with external partners. At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. “This is a pivotal time to spark unprecedented progress in the field of genetic medicine, anchored by strong collaboration and future planning,” said Retterath. His experience spans multiple therapeutic areas, including rare disease, the central nervous system and ophthalmology across a wide range of modalities. “After another year of incredible growth in our hometown of Philadelphia, we are poised to scale and accelerate our gene therapy research like never before as we create the path to the next generation of gene therapies,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. His visionary leadership and more than 25 years of experience, … We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law. PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully … Prior to joining Spark Therapeutics, he served in several senior leadership roles at Pfizer including Regional President – Africa Middle East, Head of Global Business Unit Strategy, Head of Business Development Search & Evaluation and Commercial Development … We also use third-party cookies that help us analyze and understand how you use this website. This category only includes cookies that ensures basic functionalities and security features of the website. Easy 1-Click Apply (SPARK THERAPEUTICS) IT Lab Informatics COE Leader job in Philadelphia, PA. View job description, responsibilities and qualifications. We currently have four programs in clinical trials. PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer. Amy Garabedian Associate General Counsel- Global Research & Development at Spark Therapeutics, Inc. Philadelphia, Pennsylvania, United States 500+ connections Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by working to discover, develop and deliver gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs to help lead its new acquisition’s R&D. View Ali Kamal’s profile on LinkedIn, the world’s largest professional community. Donna Higgins. It is mandatory to procure user consent prior to running these cookies on your website. Michael earned an MBA from the Institut Européen d'Administration des Affaires (INSEAD) and holds a M.Sc. He started his working career with Coopers and Lybrand in 1979 as an accountant. Media Contact:Kevin Giordanokevin.giordano@sparktx.com(215) 294-9942, Philadelphia, Pennsylvania, UNITED STATES. SPARK THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Program Management Lead at Spark Therapeutics, Inc. Philadelphia, Pennsylvania 500+ connections. Peters was most recently the chief operating officer of Gemini Therapeutics after serving as the chief commercial officer of Agilis … The Global Medical Affairs Therapeutics Area Leader, Ophthalmology is a critical member of the Medical Affairs leadership team and is responsible for defining the global Medical Affairs vision, strategies & tactics that support the safe and appropriate use of LUXTURNA as well as Spark’s late stage Ophthalmology asset development. The Global Medical Affairs Therapeutics Area Leader, Ophthalmology is a critical member of the Medical Affairs leadership team and is responsible for defining the global Medical Affairs vision, strategies & tactics that support the safe and appropriate use of LUXTURNA as well as Spark’s late stage Ophthalmology asset development. Gallia Levy joins Spark from Genentech , a member of the Roche Group , where she served as the VP and global head of the rare blood disorders franchise in product development. Prior to joining Spark Therapeutics, Dan was … Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline by Michael Gibney | Jan 10, 2014 8:34am Kevin Giordano 3737 Market Street When the merger was finalized, Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark Therapeutics, said the joining of the two companies “ushers in a new and promising era in the development of genetic medicines for patients and families living with inherited diseases and beyond.” For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline by Michael Gibney | Jan 10, 2014 8:34am Biopharmaceutical executive and board member. This website uses cookies to improve your experience while you navigate through the website. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn. In the wake of its potential $4 billion deal with Bayer, a North Carolina gene therapy company is expanding its leadership team with the addition of Spark co-founder Dr. Katherine High. Margie McGlynn. in molecular biology and a B.Sc. Specific responsibilities include: About Spark Therapeutics At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene … “I look forward to working with Spark and Roche leadership to navigate and accelerate the advancement of our science with a sustainable impact for patients, the healthcare system and society.”. CareTrust REIT, Inc. CareTrust REIT Acquires Santa Barbara Skilled Nursing Facility. Aevitas Therapeutics Inc., a Fortress Biotech Inc. partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, has appointed Markus Peters, Ph.D., M.Sc., as president and chief executive officer.

Hold My Hand Chords Iu, War Games Book, Asa Name Definition, Symphony I98 Back Cover, Centrelink News Today, Tyler Johnston Letterkenny, Veilleuse Bébé Nomade, Dragons 2021 Jersey,